Milprazon (1 - 5 kg)

1 x 2 Stück

Tablette

Wirkstoff

Praziquantel : 25 mg

Milbemycinoxim : 2,5 mg

ATC-Code

QP54AB51 Milbemycin Oxim, Komb.

QP54AB Milbemycine

QP54A Makrozyklische Lactone

QP54 Endektozide

QP Antiparasitäre Mittel, Insektizide und Repellentien

Tierarten

Small dogs and puppies (weighing at least 0.5 kg).

Diagnosen

In dogs: treatment of mixed infections by adult cestodes and nematodes of the following species:

- Cestodes: Dipylidium caninum Taenia spp.

Echinococcus spp.

Mesocestoides spp.

- Nematodes:

Ancylostoma caninum

Toxocara canis

Toxascaris leonina

Trichuris vulpis

Crenosoma vulpis (Reduction of the level of infection).

Angiostrongylus vasorum (Reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and disease prevention schedules under section 3.9 “Administration routes and dosage”).

Thelazia callipaeda (see specific treatment schedule under section 3.9 “Administration routes and dosage”).

The veterinary medicinal product can also be used in the prevention of heartworm disease (Dirofilaria immitis) if concomitant treatment against cestodes is indicated.

Wartezeit

Not applicable.

Dosierung und Art der Anwendung

Oral use.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally.

The veterinary medicinal product should be administered with or after some food.

Depending on the bodyweight of the dog, the practical dosing is as follows:

Body weight	Tablets
0.5 – 1 kg	1/2 tablet
>1 – 5 kg	1 tablet
>5 – 10 kg	2 tablets

In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, the veterinary medicinal product can replace the monovalent veterinary medicinal product for the prevention of heartworm disease.

For treatment of Angiostrongylus vasorum infections, milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against cestodes is indicated, to treat once with the veterinary medicinal product and continue with the monovalent veterinary medicinal product containing milbemycin oxime alone, for the remaining three weekly treatments.

In endemic areas administration of the veterinary medicinal product every four weeks will prevent angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where concomitant treatment against cestodes is indicated.

For the treatment of Thelazia callipaeda, milbemycin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against cestodes is indicated, the veterinary medicinal product can replace the monovalent veterinary medicinal product containing milbemycin oxime alone.

Nebenwirkungen

Dogs:

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Hypersensitivity reaction;

Systemic disorders (e.g. lethargy);

Neurological disorders (e.g. muscle tremors and ataxia);

Digestive tract disorders (e.g. emesis, diarrhoea, anorexia and drooling).

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.